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Metal Particles Are
Inappropriate for Testing a
Postulate of Extrapulmonary
Transport
Exposure to ambient air pollution particles
has been associated with increased human
morbidity and mortality, much of which is
nonpulmonary. One proposed explanation
of this extrapulmonary tissue injury is a
transport of the particles outside of the res-
piratory tract. In the August 2006 issue of
EHP, Elder et al. (2006) tested a postulate
of extrapulmonary transport of particulate
matter (PM). Specifically, the authors
focused on the potential translocation of
particles by olfactory neuronal pathways to
the central nervous system. Comparable to
previous studies on systemic transport of
PM, they used a metal particle (i.e., a man-
ganese oxide). Elder et al. measured tissue
Mn concentrations in an effort to establish
transport of the particle. 
Past research has repeatedly demon-
strated that components of PM can be solu-
bilized, mobilized, and transported to tissues
outside the respiratory tract independently
of the original particle (e.g., nicotine trans-
port from the cigarette-smoke particle to the
blood and central nervous system of the
smoker). Metals are among those compo-
nents that can be solubilized and mobilized
from particles and distributed systemically
without the translocation of the particle
from the original site of deposition in the
respiratory tract. To meet the demands of
growth and homeostasis, living systems fre-
quently acquire metals from particles using
some combination of chemical reduction
and direct chelation (Currie and Briat
2003). Elder et al. (2006) reported that the
transport of Mn, with elevated concentra-
tions of the metal in extrapulmonary tissues,
supports a translocation of the original PM
into the central nervous system. However,
their use of Mn oxide to test any postulate
of extrapulmonary transport of a particle is
inappropriate as a result of the in vivo avail-
ability of both reductants (e.g., superoxide,
ascorbate, glutathione) and chelators (e.g.,
transferrin, lactoferrin, citrate, urate) in the
mammalian respiratory tract. These reduc-
tants were not available in their in vitro solu-
bility tests (performed in normal saline), the
results of which they used to support their
conclusion of direct in vivo translocation of
particles. Elevated concentrations of the
metal in extrapulmonary tissues do not
prove direct translocation of the original
PM, but rather reflect solubilization and
mobilization of the Mn from the oxide 
particle, with subsequent distribution.
Additionally, the rapidity of change in metal
concentration at an extrapulmonary site
should not support a direct translocation
because the time required for solubilization,
mobilization, and systemic transport of a
metal from any particle has never been
defined; the required time for such transport
is predicted to be short for ultrafine parti-
cles, which have an increased surface area
available for rapid interactions of the PM
with endogenous reductants and chelators.
What is required to prove the existence of
an extrapulmonary transport of PM is
employment of a particle with components
that cannot be independently solubilized,
mobilized, and transported from the site of
its original deposition. A carbon-based PM
would be appropriate. 
When evaluating previous investigations
for evidence of extrapulmonary transport of
carbon-based particles, there is little to sup-
port translocation of such PM outside the
respiratory tract. A recent study by Mills et al.
(2006) showed no translocation of insoluble,
radiolabeled ultrafine carbon particles from
the lung into the bloodstream of humans.
The small amount of radioactivity they found
in the bloodstream and other organs within
6 hr of inhalation could be attributed entirely
to the small amount of leached, soluble radio-
label from the particles. Among miners who
were exposed to coal dust at 1,000 times the
concentrations of ambient air pollution PM,
LeFevre et al. (1982) observed the particle in
only the lung and the reticuloendothelial sys-
tem; the presence of the particle in the
reticuloendothelial system reflects the trans-
port of PM after sequestration within phago-
cytes, because the particles are always detected
within these cells at these sites. 
Finally, decades of research have pro-
vided no evidence of an extrapulmonary
transport (including via olfactory neuronal
pathways) of particles associated with ciga-
rette smoking; smoking exposes the individ-
ual to literally kilograms of a particulate
combustion product that includes ultrafine
particles. While again demonstrating that a
metal component of a particle can be solu-
bilized, mobilized, and transported from
the site of original deposition, Elder et al.
(2006) provided no evidence to support a
disbursal of the actual PM to tissues outside
the respiratory tract.
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Metal Particles and
Extrapulmonary Transport:
Oberdörster and Elder Respond
We appreciate the opportunity to address the
points raised by Ghio and Bennett in their
letter. The pH of our cell-free dissolution
studies (Elder et al. 2006) was appropriate
because the nasal cavity surface is neutral and
does not have airway macrophages and the
phagolysosomal pH of nasal epithelial cells is
neutral (Johnson 1994). Acidic pH, as in the
phagolysosome of alveolar macrophages, dis-
solves manganese oxide, resulting in
increased levels of blood-borne non-
particulate Mn. Our neutral pH buffer dis-
solved only 1.5% of Mn oxide nanoparticles
in 24 hr. The dissolution buffer was not
“normal saline,” as stated by Ghio and
Bennett; it was physiologic saline, a “simu-
lated lung fluid” used for decades in studies
of man-made fiber dissolution (Potter and
Mattson 1991). It was an oversight on our
part to omit the exact composition from our
article (Elder et al. 2006), which includes cit-
rate (model organic acid) and glycine (model
protein component). Citrate is a stronger
metal chelator than glycine.
If only soluble Mn translocates, the
time required for solubilization would sig-
nificantly retard the increase of Mn in the
olfactory bulb of administered Mn oxide
nanoparticles. Instead, we found no differ-
ence between the two forms of Mn when
we directly compared the translocation rate
of the Mn oxide nanoparticles to soluble
Mn chloride (Elder et al. 2006), indicating
a direct uptake of the Mn oxide nano-
particles by olfactory neuronal structures
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able that subsequent dissolution in the olfac-
tory system occurs. The rapidity of solid
nanoparticle transport along neuronal axons
is, indeed, remarkable (~ 2.5 mm/hr), as
demonstrated earlier by the arrival in the
olfactory bulb of 50 nm gold particles within
30 min after intranasal instillation. This and
other studies with gold nanoparticles using
transmission electron microscopy detection
(reviewed by Oberdörster et al. 2005)
demonstrate unequivocally that some metal
particles are indeed appropriate for demon-
strating solid particle transport across epithe-
lial barriers, refuting the absolute statement
in the title of Ghio and Bennett’s letter. 
Ghio and Bennett suggest that a carbon-
based particle would be appropriate for
studying ultrafine particle transport and
translocation. This is true for elemental and
organic carbon only if insoluble in vivo.
Indeed, study with inhaled ultrafine elemen-
tal carbon particles (13C) confirmed their
translocation to the olfactory bulb of rats
(Oberdörster et al. 2004). In contrast,
labeled elemental carbon is problematic, as
pointed out by Ghio and Bennett regarding
Technegas (99mTc labeled-ultrafine carbon).
Recent studies using inhaled Technegas
(Mills et al. 2006; Wiebert et al. 2006)
showed no translocation in humans, contra-
dicting earlier work (Nemmar et al. 2002).
Both leaching of the soluble radiolabel and
the inability of the g-camera to detect small
amounts (£ 1%) of the deposited dose in
extrapulmonary organs are significant limi-
tations with this noninvasive technique,
resulting in misinterpretions suggesting
either significant particle translocation or
lack thereof.
Ghio and Bennett cite LeFevre et al.
(1982), apparently as evidence that inhaled
carbon-based particles do not undergo extra-
pulmonary transport. However, LeFevre et al.
interpreted their findings of high black pig-
ment scores in liver and spleen of coal miners
differently—namely, as migration of coal
dust in the pneumoconiotic lung into pul-
monary lymphatics and then to the systemic
circulation, and also as migration of coal
mine dust–laden macrophages through the
walls of pulmonary blood vessels. Whatever
the mechanism, their findings clearly indicate
extrapulmonary transport. Heavy silica
inhalation exposure has also been found to
result in particle accumulation in liver and
other extrapulmonary tissues in humans and
nonhuman primates (Carmichael et al. 1980;
Rosenbruch 1990; Slavin et al. 1985). Ghio
and Bennett further state that 
Decades of research have provided no evidence of
an extrapulmonary transport (including via olfac-
tory neuronal pathways) of particles associated
with cigarette smoking.
How many investigators have tried to find
cigarette smoke particles in extrapulmonary
tissues? We are aware of only one study in
rats in which a 25-min inhalation exposure to
14C cigarette smoke resulted in 0.24–0.83%
of retained 14C in the liver within 15 min
after the short-term exposure (Chen et al.
1989). Does this indicate extrapulmonary
particle transport? Possibly yes.
We conclude that the physicochemical
characteristics of a nanoparticle—whether
metal or not—and the physiologic milieu at
the site of deposition in the respiratory tract
determine whether extrapulmonary trans-
location occurs as particle or as solute. A
prerequisite for noninvasively measuring
this is that the detection method has suffi-
cient sensitivity for identifying the analyte
at expected low translocation rates.
Regarding our nasal translocation study
in rats (Elder et al. 2006), we conclude that
inhaled Mn oxide nanoparticles are taken up
by the nasal olfactory neuronal pathway as
solid particles rather than being slowly dis-
solved first at neutral pH. For the alveolar
region where dissolution is expected to be
more rapid, this does not apply.
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Limitations of WTC Five-Year
Assessment
We have learned much about the respiratory
disorders since the exposures of responders
at the World Trade Center (WTC) site,
especially from the publications of Prezant
and colleagues about the presentations, fol-
low-up, and impairments of pulmonary
function and bronchial reactivity of the fire
fighters and emergency medical technicians
of the New York City Fire Department
(Banauch et al. 2003, 2005, 2006; Prezant
et al. 2002). These reports are especially
informative because of the availability of
preexposure clinical and spirometric data.
We appreciate the report of much-
awaited results among 9,442 workers from
the WTC Worker and Volunteer Medical
Screening Program (Herbert et al. 2006).
Because of the potential for major illness,
the large number of subjects at risk, and the
resultant enormous public interest, it is
important that the information reported be
properly understood. A number of limita-
tions in this report must be pointed out.
Although the title identified this report
(Herbert et al. 2006) as a 5-year assessment,
screening examinations were performed
between 16 July 2002 and 16 April 2004,
< 1 year through < 3 years after 11 September
2001. There were no follow-up examina-
tions, either at the 5-year or at any other
interval.
Summary conclusions (Herbert et al.
2006), heavily reported in the media, lump
all respiratory symptoms: 
… 69% reported new or worsened respiratory
symptoms while performing WTC work.
Symptoms persisted to the time of examination
in 59% of these workers. 
The 69% with “any respiratory symptom”
included 23.3% with no “lower respiratory
symptoms.” A far smaller percentage of all
workers (17.3%) complained of what may
be considered the most important respira-
tory symptom, dyspnea, which was not
quantified by any standard scale. Such a
reliance on symptoms is subject to recall
biases both for symptoms present before
9/11 and for the onset, worsening, and per-
sistence of symptoms after 9/11.
Because physical examination and chest
radiographs were unrevealing (Herbert et al.
2006), the only objective results were from
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fined to spirometry, which does not provide
insight into all aspects of respiratory impair-
ment. The data presented by Herbert et al.
(2006) are limited. Mean values for subsets
(classified by WTC exposure, previous
smoking history, etc.) are not given. Despite
the frequency of cough (42.8%), wheeze
(15.1%), and chest tightness (15.4%) and
the common diagnoses of asthma/reactive
airways dysfunction, only 7.6% of all
responders showed airway obstruction,
defined as a ratio of forced expiratory vol-
ume in 1 sec (FEV1) to forced vital capacity
(FVC) less than the 5th percentile of the ref-
erence population. Unlike virtually all spiro-
metric surveys of a large population
(reviewed by Miller et al. 1991), Herbert et al.
(2006) found little difference in impairment
by smoking status. Most spirometric impair-
ments were classified as restrictive, uncharac-
teristic of the symptoms and clinical
diagnoses. This frequency of low FVC
(22.7%) raises several issues: a) the effects of
other clinical factors not reported on, such
as obesity; b) technical considerations in
subject performance or technician monitor-
ing of the FVC maneuver, despite the inves-
tigators attention to these; and c)t h e
appropriateness of the reference-predicted
values.
We await further information and follow-
up from these investigators, including results
of additional diagnostic procedures not
included in routine screening. These include
a wider array of pulmonary function tests
(full lung volumes, diffusing capacity),
measurement of bronchial reactivity, com-
puted tomography scans, and—in appropri-
ate patients—bronchoalveolar lavage and
lung biopsies, which would truly elucidate
the respiratory disorders following WTC
exposure.
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WTC Five-Year Assessment:
Herbert et al. Respond
In our article (Herbert et al. 2006), we
described the establishment of the World
Trade Center (WTC) Worker and Volun-
teer Medical Screening Program and pre-
sented results of screening examinations
undertaken between 2002 and 2004 among
a heterogeneous group of 9,442 WTC
responders.
Miller expresses concern about the
validity of self-reported upper and lower
respiratory symptoms in WTC responders.
He notes correctly that self-reported symp-
toms are inherently subjective. However,
symptoms cannot merely be dismissed as
unimportant, especially when they are per-
sistent and when, as was the case here, the
pattern of their occurrence closely parallels
severity of exposure. We reported that
symptoms were most common among
those responders who arrived earliest at the
WTC site and who consequently suffered
the heaviest exposures to the highest levels
of dust and smoke (Herbert et al. 2006).
This finding has high inherent biological
plausibility. To be sure, the potential for
recall bias is always present in a symptom-
based survey. In reality, however, recall
bias could be of concern only if we had
reason to believe that responders in differ-
ent exposure groups recalled past and cur-
rent symptomatology differently. Finally,
to further ensure the validity of our find-
ings, we buttressed our assessment of
symptoms with chest X rays and pul-
monary function tests. 
Miller also expresses concern that objec-
tive results were “confined to spirometry,
which does not provide insight into all
aspects of respiratory impairment.” Although
we recognize the limitations of spirometry,
a large-scale screening program has practical
restrictions in testing that can be accom-
plished. In fact, in Miller’s own 1991 sur-
vey of a population 10 times smaller than
our own (Miller et al. 1991), only spirome-
try was used as a screening tool. Miller
observes that our results were “unlike virtu-
ally all spirometric surveys of a large popu-
lation” since there was “little difference in
impairment by smoking status.” We would
agree with Miller that our population was
distinct by the very nature of the exposures
involved and that this should be considered
in evaluating the lack of difference in
impairment based on smoking status. One
speculation is that the overwhelming expo-
sure to toxic chemicals at the WTC disaster
may have masked differences between
smokers and nonsmokers.
Miller erroneously states that most
spirometric impairments were classified as
“restrictive.” We were quite careful not to
use this term because it cannot be con-
firmed by spirometry alone. Instead we
chose the designation of low forced vital
capacity (FVC) (Herbert et al. 2006). Like
Miller, we were surprised by this finding as
well as by the observation that fewer respon-
ders had reversible airway obstruction,
which would have confirmed asthma in
those with asthma-like symptoms. However,
asthma is by its very nature intermittent,
and spirometry tests are only a “snapshot in
time,” so normal spirometry results do not
rule out asthma. Unfortunately, we were
unable to provide inhalation challenge tests
for the cohort because of the constraints of
conducting a large multicenter clinical
screening program. 
We listed the many possible reasons for
a high prevalence of a low FVC in the
“Discussion” of our article (Herbert et al.
2006). One member of our working group
(G.S.) is currently leading an initiative to
estimate the individual contribution of each
of these factors by describing the results of
additional diagnostic procedures not
included in routine screening. 
Examinations of the WTC population
continue and are expected to proceed for
many years to come. As of 31 December
2006, we have examined > 18,500 WTC
responders and provided follow-up exami-
nations to > 7,000. We expect to report on
findings from those examinations within
the next year. In addition, we will be
reporting further on the relationship
between symptoms and screening spirome-
try. These analyses should provide further
insight into the potential pulmonary
impairment of individuals exposed at the
WTC disaster.
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ERRATUM
In Table 2 of the the commentary by
Marsee et al. [Environ Health Perspect
114:805–809 (2006)], the value for
the 75th percentile of monobenzyl
phthalate (MBzP) was incorrect; the
correct value is 0.92.
The authors regret the error.